-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

Benzinga·09/29/2026 16:54:15
语音播报
Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $21 to $30.